HUTCHMED and AstraZeneca Submit US NDA for ORPATHYS Plus TAGRISSO
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026 HUTCHMED (China) Limited announced that AstraZeneca has submitted...
Osimertinib
Advertisement
Iterion Therapeutics Reports Positive Tegavivint Phase 1b Data
Houston, Texas, U.S., September 22, 2026 Iterion Therapeutics has announced promising results from a Phase 1b clinical study evaluating...
AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer
Wilmington, Delaware, U.S., September 14, 2026 AstraZeneca announced updated results from the Phase III ADAURA trial, showing sustained long-term...
Kazia Paxalisib Shows Potential in Resistant Colorectal Cancer
Sydney, Australia, September 1, 2026 Kazia Therapeutics Limited has reported new preclinical and translational findings suggesting that its investigational...
HUTCHMED Reports Phase III Lung Cancer Trial Success
Hong Kong, Shanghai, China, and Florham Park, New Jersey, August 31, 2026 HUTCHMED (China) Limited has announced positive high-level...
Advertisements
HUTCHMED Reports Phase III SANOVO PFS Benefit in EGFR NSCLC
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...
HUTCHMED and AstraZeneca Advance ORPATHYS-TAGRISSO Lung Cancer Combination
Hong Kong, Shanghai & Florham Park, N.J., Aug. 17, 2026 HUTCHMED (China) Limited announced positive high-level results from the...
Kairos Announces Positive Interim Phase 1 ENV-105 Data
LOS ANGELES, July 15, 2026 Kairos Pharma announced encouraging interim safety results from its ongoing Phase 1 clinical trial...
Abbisko and AstraZeneca Advance Oral PD-L1 Therapy for NSCLC
SHANGHAI, China, July 1, 2026 Abbisko Therapeutics and AstraZeneca have entered into a strategic collaboration to advance the clinical...
Advertisement
